ಪ್ರಾಸ್ಟೇಟ್ ಕ್ಯಾನ್ಸರ್
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
ಎಲ್ಲಿಗೆ ಹೋಗಬೇಕು
ಭಾರತದ 8 ಆಸ್ಪತ್ರೆಗಳು ಈ trial-ಗೆ ರೋಗಿಗಳನ್ನು ಸೇರಿಸಿಕೊಳ್ಳುತ್ತಿವೆ.
ರಿಜಿಸ್ಟ್ರಿ ಸಾರಾಂಶ (ತಾಂತ್ರಿಕ)
Researchers are looking for a better way to treat men who have non-metastatic castration-resistant prostate cancer (nmCRPC). This is a type of cancer of the prostate that has not yet spread to other parts of the body and that keeps progressing even when the amount of male sex hormones like testosterone (also called androgens) is reduced to very low levels. To reduce androgen levels in prostate cancer patients, androgen deprivation therapy (ADT) is often used. As androgens stimulate the growth of prostate cancer cells, low levels are needed to reduce or slow the growth of these tumors. In men …
Sponsor: Bayer
ClinicalTrials.gov ನಲ್ಲಿ NCT05348876
Last updated on the registry 6 Jul 2026 · read by us 20 Oct 2026